These findings highlight the necessity of line specific therapeutic decision making and clarify the roles of anti-EGFR/BRAF based treatment strategies in patients with advanced BRAF-mutated colorectal cancer, potentially complementing the current guidelines. Here, EGFR is linked to colorectal cancer.